Marshall Edwards starts Phase 1 cancer trial
Marshall Edwards (NASDAQ:MSHL) has initiated a Phase 1 clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors in collaboration with the Sarah Cannon Research Institute in Nashville, Tenn.
The Phase 1 dose-escalation trial will evaluate the safety and tolerability of intravenous ME-143, characterize the pharmacokinetic profile of intravenous ME-143 and describe any preliminary clinical anti-tumor activity observed. The open-label trial is expected to enrol up to 24 patients, with final data collected by the second quarter of 2012.
“Together with the Sarah Cannon Research Institute, we will be obtaining important information regarding dosing, safety and potential efficacy of intravenous ME-143 over the next several months, which will inform the design of our randomized Phase 2 clinical trials in combination with standard-of-care chemotherapy,” Marshall Edwards CMO Dr. Robert Mass said in a statement.